Pocket related complications in 163 patients receiving anticoagulation or dual antiplatelet therapy: D-Stat Hemostat™ versus standard of care

International Journal of Cardiology

Volumn 159, Issue 3, 2012, Pages 177-180

  Ohlow, Marc Alexander ^a   Lauer, Bernward ^a   Buchter, Bjoern ^a   Schreiber, Matthias ^a   Geller, J Christoph ^b  

^a Zentralklinik Bad Berka ^*  (Germany)

^b ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Anticoagulation; D stat Flowable Hemostat ; Dual antiplatelet therapy; Infection; Pacemaker; Pocket hematoma

Indexed keywords

C REACTIVE PROTEIN; COLLAGEN; IMMUNOGLOBULIN E; THROMBIN;

ADJUVANT THERAPY; AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DEVICE INFECTION; DEVICE SAFETY; FATALITY; FEMALE; HEMATOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; PNEUMOTHORAX; POCKET HEMATOMA; POCKET INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMATOMA; HUMANS; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; STANDARD OF CARE;

EID: 84865496957     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.02.042     Document Type: Article

References (23)

1. C. Kearon, and J. Hirsh Management of anticoagulation before and after elective surgery N Engl J Med 336 1997 1506 1511
2. J. Tolosana, P. Berne, and L. Mont Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomised trial Eur Heart J 30 2009 1880 1884
3. M. Guidici, S. Barold, D. Paul, and P. Bontu Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy PACE 27 2004 358 360
4. H. von Korn, J. Yu, and M. Ohlow Interventional therapy of bifurcation lesions: a Timi-flow-guided concept to treat side branches in bifurcation lesions-a prospective randomized clinical study Circ Cardiovasc Interv 2 6 2009 535 542
5. D. Klug, M. Balde, and D. Pavin Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators Circulation 116 2007 1349 1355
6. M. Brunner, M. Olschewski, A. Geibel, C. Bode, and M. Zehender Long-term survival after pacemaker implantation. Prognostic importance of gender and baseline patient characteristics Eur Heart J 25 1 2004 88 95
7. S. Bergel Über die Wirkung des Fibrins Dtsch Med Wochenschr 35 1909 663 665
8. K. Gdanietz, and I. Gutsche The use of fibrin sealant in surgery Acta Chir Austriaca 3 1991 95 99
9. F. DeLustro, R. Condell, M. Ngyen, and J. McPherson A comparative study of the biologic and immunologic response to medical devices derived from dermal collagen J Biomed Mater Res 20 1986 109 120
10. L. Baddour, M. Bettmann, and A. Bolger Nonvalvular device-related infections Circulation 108 2003 2015 2031
11. D. Slotwiner, S. Alder, and C. Fuenzalida The pocket protector study: use of D-stat flowable hemostat in pulse generator pectoral pockets reduces the rate of clinically relevant hematomas (Abstract) Circulation 116 2007 II-678
12. D. Diesen, and J. Lawson Bovine thrombin: history, use, and risk in the surgical patient Vascular 16 Supp I 2008 29 36
13. C. Lomax Safety of topical thrombins: the ongoing debate Patient Saf Surg 3 2009 21 24
14. G. Hill Enhancement of experimental anaerobic infection by blood, haemoglobin, and hemostatic agents Infect Immun 19 1978 443 449
15. D. Milic, Z. Perisic, and S. Zivic Prevention of pocket related complications with fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulation treatment Europace 7 2005 374 379
16. D. Thompson, N. Letassy, and G. Thompson Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical haemostat Drug Intell Clin Pharm 22 1988 946 952
17. R. Senderoff, M. Sheu, and T. Sokoloski Fibrin based drug delivery systems J Parenter Sci Technol 45 1991 2 6
18. Y. Tomizawa Clinical benefits and risk analysis of topical hemostats: a review J Artif Organs 8 2005 137 142
19. R. Timpl Immunology of the collagens K. Piez, A. Reddy, Extracellular matrix biochemistry 1984 Elsevier New York 159 190
20. K. Stenzel, T. Miata, and A. Rubin Collagen as a biomaterial Annu Rev Biophys Bioeng 3 1974 231 253
21. J. Ibarrola, J. Bjorenson, B. Austin, and H. Gerstein Osseous reactions to hemostatic agents J Endod 11 1985 75 83
22. J. jorenson, H. Grove, M. List, G. Haasch, and B. Austin Effects of hemostatic agents on the pH of body fluids J Endod 12 1986 289 292
23. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2